Clinical Trial Update: Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of SGN-40, lenalidomide, and dexamethasone in multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• SGN-40 (dacetuzumab)

Snippet

Sponsor: Seagen Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED